tbuckley/cabot-search huggingface dataset:
Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors
Authors: Gemma A. Figtree, Stephen T. Vernon, Jason A. Harmer, Michael P. Gray, Clare Arnott, Eric Bachour, Giannie Barsha, David Brieger, Alex Brown, David S. Celermajer, Keith M. Channon, Nicholas W.S. Chew, James J.H. Chong, Clara K. Chow, Peter A. Cistulli, Patrick T. Ellinor, Stuart M. Grieve, Tomasz J. Guzik, Emil Hagström, Alicia Jenkins, Garry Jennings, Anthony C. Keech, Katharine A. Kott, Leonard Kritharides, Mamas A. Mamas, Roxana Mehran, Peter J. Meikle, Pradeep Natarajan, Kazuaki Negishi, John O’Sullivan, Sanjay Patel, Peter J. Psaltis, Julie Redfern, Philippe G. Steg, David R. Sullivan, Johan Sundström, Birgit Vogel, Andrew Wilson, Dennis Wong, Deepak L. Bhatt, Jason C. Kovacic, Stephen J. Nicholls, Zanfina Ademi, Suzanne Robyn Avis, Adam Chan, Osvaldo Contreras, Craig P. Coorey, Sina Fathieh, Elijah Genetzakis, Alireza Gholipour, Corey Giles, Matthew Hollings, Karice Hyun, Samia Kazi, Jason C. Kovacic, Mark Larance, Jessica A. Marathe, Clara Marquina, Adam Nelson, Hooi Hooi Ng, Ellis Patrick, Karlheinz Peter, Andy Tran, Jean Yang, Dantong Zhu, Clara Zwack
Journal: Journal of the American College of Cardiology (2023)

Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is lacking. We assembled an international, multidisciplinary team to develop an evidence-based clinical pathway for SMuRFless CAD patients. A modified Delphi method was applied. The resulting pathway confirms underlying atherosclerosis and true SMuRFless status, ensures evidence-based secondary prevention, and considers additional tests and interventions for less typical contributors. This dedicated pathway for a previously overlooked CAD population, with an accompanying registry, aims to improve outcomes through enhanced adherence to evidence-based secondary prevention and additional diagnosis of modifiable risk factors observed.
Association of High-Sensitivity Cardiac Troponin T With 30-Day and 5-Year Mortality After Cardiac Surgery
Authors: Leo Pölzl, Clemens Engler, Philipp Sterzinger, Ronja Lohmann, Felix Nägele, Jakob Hirsch, Michael Graber, Jonas Eder, Sebastian Reinstadler, Nikolay Sappler, Juliane Kilo, Ivan Tancevski, Sebastian Bachmann, Hannes Abfalterer, Elfriede Ruttmann-Ulmer, Hanno Ulmer, Andrea Griesmacher, Samuel Heuts, Matthias Thielmann, Axel Bauer, Michael Grimm, Nikolaos Bonaros, Johannes Holfeld, Can Gollmann-Tepeköylü
Journal: Journal of the American College of Cardiology (2023)
Transcatheter Edge-to-Edge Repair in 5,000 Patients With Secondary Mitral Regurgitation
Authors: Kashish Goel, JoAnn Lindenfeld, Raj Makkar, Hursh Naik, Satya Atmakuri, Paul Mahoney, Michael A. Morse, Vinod H. Thourani, Pradeep Yadav, Wayne Batchelor, Jason Rogers, Brian Whisenant, Michael Rinaldi, James Hermiller, Brian R. Lindman, Colin M. Barker
Journal: Journal of the American College of Cardiology (2023)
Endoscopic ultrasound-guided gastroenterostomy: another knock-out for simplification
Authors: Michiel Bronswijk, Schalk van der Merwe
Journal: Endoscopy (2023)

In the last decade, EUS-guided gastroenterostomy (EUS-GE) has evolved into a first-line approach to managing patients with malignant gastric outlet obstruction (GOO) [1]. During this timeframe we have witnessed a surge in clinical data, evolving from small retrospective series into matched multicenter comparisons, prospective series, and more recently randomized controlled trials (RCTs) [2] [3] [4]. The results of the first RCT to be made available seem to confirm previous findings [3], showing that EUS-GE has overcome the limitations of duodenal stenting whilst achieving a similar safety profile [4]. Although its efficacy has been proven beyond any doubt and maldeployment subtypes have been defined, safety and patient selection have remained inadequately explored to date [5] [6]. This mostly stems from the fact that the procedure had not been standardized, complicating comparisons between approaches.
Biliary cannulation in ERCP: you don’t need to be a shark if you now can be sharp!
Authors: Andrea Anderloni
Journal: Endoscopy (2023)

Cannulation is the mainstay of endoscopic retrograde cholangiopancreatography (ERCP). Besides being the first step of ERCP, cannulation is actually often the most difficult step of the procedure and failure can preclude all the next steps. Several decades of ERCP as an established procedure, as well as the definition and implementation of training programs, have contributed to achieving a reference standard in ERCP competence, including cannulation rate, for which a minimum cutoff of ≥ 80 % is proposed by European Society of Gastrointestinal Endoscopy (ESGE) [1]. However, a non-negligible rate of cannulation failure is still reported in clinical practice studies [2] [3]. Cases of failure are mainly related to the morphology of the major papilla, the presence of a periampullary diverticulum, or pancreatic or ampullary cancer, and inexperience of the endoscopist [4]. Moreover, it is worth considering that advanced cannulation techniques in cases of difficult cannulation carry a higher risk of post-ERCP pancreatitis (PEP), perforation, and bleeding [5]. More recently, the evolution of cholangioscopy devices has allowed direct visualization of the bile duct during ERCP [6], just like colonoscopy did 50 years ago for direct visualization of the colon. Literature about the use of cholangioscopy has focused on the diagnostic assessment of indeterminate strictures, treatment of complex bile duct stones, and selective cannulation of complex biliary strictures [7] [8] [9]. No reports on the use of cholangioscopy for selective biliary cannulation have been published to date.
Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study
Authors: Mariam Elmegaard Malik, Jawad Haider Butt, Jarl Emanuel Strange, Alexander Christian Falkentoft, Jesper Jensen, Charlotte Andersson, Deewa Zahir, Emil Fosbøl, Mark C Petrie, Naveed Sattar, John J V McMurray, Lars Køber, Morten Schou
Journal: The Lancet Healthy Longevity (2023)

Whether frailty influences the initiation of two cardioprotective diabetes drug therapies (ie, SGLT2 inhibitors and GLP-1 receptor agonists) in people with type 2 diabetes and cardiovascular disease is unknown. We aimed to assess rates of initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to frailty in people with type 2 diabetes and cardiovascular disease.For this cross-sectional, nationwide study, all people with type 2 diabetes and cardiovascular disease in Denmark between Jan 1, 2015, and Dec 31, 2021, from six Danish health-data registers were identified. People younger than 40 years, with end-stage renal disease, with registered contraindications to SGLT2 inhibitors or GLP-1 receptor agonists, or with previous use of either drug therapy were excluded. The Hospital Frailty Risk Score was used to categorise people as either non-frail, moderately frail, or severely frail. Cox proportional hazards models were used to analyse the association between frailty and initiation of an SGLT2 inhibitor or a GLP-1 receptor agonist.Of 119 390 people with type 2 diabetes and cardiovascular disease, 103 790 were included. Median follow-up time was 4·5 years (IQR 2·7-6·1) and median age across the three frailty groups was 71 years (64-79). 65 959 (63·6%) of 103 790 people were male and 37 831 (36·5%) were female. At index date, 66 910 (64·5%) people were non-frail, 29 250 (28·2%) were moderately frail, and 7630 (7·4%) were severely frail. Frailty was associated with a significantly lower probability of initiating therapy with an SGLT2 inhibitor or a GLP-1 receptor agonist than in people who were non-frail (moderately frail hazard ratio 0·91, 95% CI 0·88-0·94, p<0·0001; severely frail 0·75, 0·70-0·80, p<0·0001). This association persisted after adjustment for age, sex, socioeconomic status, year of inclusion, duration of type 2 diabetes, duration of cardiovascular disease, polypharmacy, and comorbidity.In people with type 2 diabetes and cardiovascular disease in Denmark, frailty was associated with a significantly lower probability of SGLT2-inhibitor or GLP-1 receptor-agonist initiation, despite their benefits. Formulating clear and updated guidelines on the use of SGLT2 inhibitors and GLP-1 receptor agonists in people who are frail with type 2 diabetes and cardiovascular disease should be a priority.Department of Cardiology, Herlev and Gentofte University Hospital.For the Danish translation of the abstract see Supplementary Materials section.
Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant
Authors: Keiya Uriu, Jumpei Ito, Yusuke Kosugi, Yuri L Tanaka, Yuka Mugita, Ziyi Guo, Alfredo A Hinay, Olivia Putri, Yoonjin Kim, Ryo Shimizu, MST Monira Begum, Michael Jonathan, Akatsuki Saito, Terumasa Ikeda, Kei Sato
Journal: The Lancet Infectious Diseases (2023)
Iron deficiency in myocardial ischaemia: molecular mechanisms and therapeutic perspectives
Authors: Francesco Corradi, Gabriele Masini, Tonino Bucciarelli, Raffaele De Caterina
Journal: Cardiovascular Research (2023)

Abstract Systemic iron deficiency (SID), even in the absence of anaemia, worsens the prognosis and increases mortality in heart failure (HF). Recent clinical–epidemiological studies, however, have shown that a myocardial iron deficiency (MID) is frequently present in cases of severe HF, even in the absence of SID and without anaemia. In addition, experimental studies have shown a poor correlation between the state of systemic and myocardial iron. MID in animal models leads to severe mitochondrial dysfunction, alterations of mitophagy, and mitochondrial biogenesis, with profound alterations in cardiac mechanics and the occurrence of a fatal cardiomyopathy, all effects prevented by intravenous administration of iron. This shifts the focus to the myocardial state of iron, in the absence of anaemia, as an important factor in prognostic worsening and mortality in HF. There is now epidemiological evidence that SID worsens prognosis and mortality also in patients with acute and chronic coronary heart disease and experimental evidence that MID aggravates acute myocardial ischaemia as well as post-ischaemic remodelling. Intravenous administration of ferric carboxymaltose (FCM) or ferric dextrane improves post-ischaemic adverse remodelling. We here review such evidence, propose that MID worsens ischaemia/reperfusion injury, and discuss possible molecular mechanisms, such as chronic hyperactivation of HIF1-α, exacerbation of cytosolic and mitochondrial calcium overload, amplified increase of mitochondrial [NADH]/[NAD+] ratio, and depletion of energy status and NAD+ content with inhibition of sirtuin 1–3 activity. Such evidence now portrays iron metabolism as a core factor not only in HF but also in myocardial ischaemia.
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
Authors: John V Reynolds, Shaun R Preston, Brian O'Neill, Maeve A Lowery, Lene Baeksgaard, Thomas Crosby, Moya Cunningham, Sinead Cuffe, Gareth O Griffiths, Imelda Parker, Signe Lenora Risumlund, Rajarshi Roy, Stephen Falk, George B Hanna, Frederick R Bartlett, Alberto Alvarez-Iglesias, Michael P Achiam, Magnus Nilsson, Guillaume Piessen, Narayanasamy Ravi, Dermot O'Toole, Ciaran Johnston, Raymond S McDermott, Richard C Turkington, Shajahan Wahed, Sharmila Sothi, Hugo Ford, Martin S Wadley, Derek Power, Somnath Mukherjee, Carys Morgan, Simon L Parsons, Neel Bhuva, Sorcha Campbell, Liam Grogan, Greg Leonard, Andrew R Bateman, Catherine Mitchell, Seamus O'Reilly, Eibhlin Mulroe, Olivia McLoughlin, Anna Shevlin, Aoife M Shannon, Jacinta Marron, Marc Nolan, Grace Burch, Michelle Costello, Daniel Griffiths, Kelly Cozens, Emma Foley, Claire L Donohoe, Catherine O'Farrell, Jennifer Moore, Jacintha O'Sullivan
Journal: The Lancet. Gastroenterology & hepatology (2023)

The optimum curative approach to adenocarcinoma of the oesophagus and oesophagogastric junction is unknown. We aimed to compare trimodality therapy (preoperative radiotherapy with carboplatin plus paclitaxel [CROSS regimen]) with optimum contemporaneous perioperative chemotherapy regimens (epirubicin plus cisplatin or oxaliplatin plus fluorouracil or capecitabine [a modified MAGIC regimen] before 2018 and fluorouracil, leucovorin, oxaliplatin, and docetaxel [FLOT] subsequently).
Synergistic Approach of Antibody‐Photosensitizer Conjugate Independent of KRAS‐Mutation and Its Downstream Blockade Pathway in Colorectal Cancer
Authors: Minji Ahn, Taebum Lee, Kyoung Sub Kim, Sanghee Lee, Kun Na
Journal: Advanced Healthcare Materials (2023)

Here, a novel approach is presented to improve the efficacy of antibody-drug conjugates (ADC) by integrating antibody-mediated immunotherapy and photodynamic therapy (PDT) in a combination therapy system utilizing an antibody-photosensitizer conjugate (APC) platform based on a poloxamer polymer linker. To specifically target Kirsten rat sarcoma 2 viral oncogene homolog (KRAS)-mutated cancer cells, an antibody antiepidermal growth factor receptor (EGFR), cetuximab, with a poloxamer linker coupled with the photosensitizer chlorin e6 through click chemistry (cetuximab-maleimide-poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)-chlorine e6 conjugate, CMPXC) is synthesized. CMPXC is cytotoxic upon laser treatment, achieving a 90% cell death by suppressing KRAS downstream signaling pathways associated with ERK and AKT proteins, confirmed using RNA sequencing analysis. In KRAS-mutated colorectal cancer mouse models, CMPXC significantly enhances antitumor efficacy compared with cetuximab treatment alone, resulting in an 86% reduction in tumor growth. Furthermore, CMPXC treatment leads to a 2.24- and 1.75-fold increase in dendritic and priming cytotoxic T cells, respectively, highlighting the immune-activating potential of this approach. The findings suggest that the APC platform addresses the challenges associated with ADC development and EGFR-targeted therapy, including the synergistic advantages of antibody-mediated immunotherapy and PDT.
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2)
Authors: Amir Qaseem, Jennifer Yost, George M. Abraham, Rebecca Andrews, Janet A. Jokela, Matthew C. Miller, Linda L. Humphrey, Linda L. Humphrey, Adam J. Obley, Elie A. Akl, Rebecca Andrews, Andrew Dunn, Mary Ann Forciea, Ray Haeme, Janet A. Jokela, Devan L. Kansagara, Rachael Lee, Katherine Mackey, Maura Marcucci, Matthew C. Miller, Sameer D. Saini, CDR Mark P. Tschanz, Timothy J. Wilt, Kate Carroll, Itziar Etxeandia-Ikobaltzeta, Curtis Harrod, Amir Qaseem, Tatyana Shamliyan, Karla Umana, Jennifer Yost
Journal: Annals of Internal Medicine (2023)

Evidence for the use of outpatient treatments in adults with confirmed COVID-19 continues to evolve with new data. This is version 2 of the American College of Physicians (ACP) living, rapid practice points focusing on 22 outpatient treatments for COVID-19, specifically addressing the dominant SARS-CoV-2 Omicron variant.
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2)
Authors: Isolde Sommer, Dominic Ledinger, Kylie Thaler, Andreea Dobrescu, Emma Persad, Martin Fangmeyer, Irma Klerings, Gerald Gartlehner
Journal: Annals of Internal Medicine (2023)

Clinicians and patients want to know the benefits and harms of outpatient treatment options for the Omicron variant of SARS-CoV-2.
What You Deserve
Authors: Michael Slade
Journal: Annals of Internal Medicine (2023)

Ad LibitumSeptember 2023What You DeserveMichael Slade, MD, MSCIMichael Slade, MD, MSCIWashington University School of Medicine, St. Louis, MissouriSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M23-1044 Audio Reading - “What You Deserve” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “What You Deserve” by Michael Slade, MD, MSCI Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I know what you deserve.A set of rooms, made readyfor friends and familytraveling from distant landsto cherish your last week.A nurse for every hourso your children's memorieswon't be of packing your woundsor sponging your genitals.A serene confidence,free from worry about losingyour house or consuminga lifetime of work in days.I know what you deserve.The words crash on my skulllike waves against a cliffas I shift uncomfortably, buryingmy hands in nonexistent pockets.You're human, after alla universe slowly unwinding,each memory annihilatedin a private catastrophe.my mind screaming for respite... Author, Article, and Disclosure InformationAuthors: Michael Slade, MD, MSCIAffiliations: Washington University School of Medicine, St. Louis, MissouriCorresponding Author: Michael Slade, MD, MSCI, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110; e-mail, michaeljslade@gmail.com. PreviousarticleNextarticle Advertisement Audio Reading - “What You Deserve” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “What You Deserve” by Michael Slade, MD, MSCI Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics September 2023Volume 176, Issue 9 Page: 1281 ePublished: 19 September 2023 Issue Published: September 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Annals Consult Guys - Spontaneous Coronary Artery Dissection
Authors: Howard H. Weitz, Geno J. Merli
Journal: Annals of Internal Medicine (2023)

Web ExclusivesSeptember 2023Annals Consult Guys - Spontaneous Coronary Artery DissectionFREEHoward H. Weitz, MD, and Geno J. Merli, MDHoward H. Weitz, MDThomas Jefferson University, Philadelphia, Pennsylvania (H.H.W., G.J.M.)Search for more papers by this author, and Geno J. Merli, MDThomas Jefferson University, Philadelphia, Pennsylvania (H.H.W., G.J.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W22-0022 CME/MOC SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The Annals Consult Guys discuss a patient who had a myocardial infarction due to spontaneous coronary artery dissection. Why did this happen? Can anything be done to reduce the risk of it happening again?For more videos from and information on Annals Consult Guys, visit go.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Howard H. Weitz, MD; Geno J. Merli, MDAffiliations: Thomas Jefferson University, Philadelphia, Pennsylvania (H.H.W., G.J.M.)Disclosures: Drs. Merli and Weitz report that they have no financial relationships or interests to disclose. All relevant financial relationships have been mitigated. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=W22-0022.Editors' Disclosures: The editors have no relevant financial relationships to disclose. Individual forms may be viewed at www.annals.org/editorsdisclosures. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Current IssueSeptember 2023Volume 176, Issue 9 ePublished: 19 September 2023 Issue Published: September 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.Loading ...
Lessons Learned While Grieving
Authors: Ronenn Roubenoff
Journal: Annals of Internal Medicine (2023)

On Being a DoctorSeptember 2023Lessons Learned While GrievingRonenn Roubenoff, MDRonenn Roubenoff, MDBrookline, MassachusettsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M23-1704 Audio Reading - “Lessons Learned While Grieving” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Lessons Learned While Grieving” by Ronenn Roubenoff, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In the 40 years since I graduated from medical school, I have become an expert at a few abstruse areas of medicine, from aging and loss of muscle and independence to the arcane arts of drug development and various kinds of and treatments for arthritis. Unfortunately, I also became an expert at something else: losing wives to incurable diseases. Rebecca died of cancer in 1991, Abby from a different type of cancer in 2005, and Barri from ALS in 2022. You might say that I’ve been unlucky, though I would argue that having been married to three amazing women for ... Author, Article, and Disclosure InformationAuthors: Ronenn Roubenoff, MDAffiliations: Brookline, MassachusettsCorresponding Author: Ronenn Roubenoff, MD; e-mail, rroubenoff@gmail.com. PreviousarticleNextarticle Advertisement Audio Reading - “Lessons Learned While Grieving” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Lessons Learned While Grieving” by Ronenn Roubenoff, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics September 2023Volume 176, Issue 9 Page: 1279-1280 ePublished: 19 September 2023 Issue Published: September 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Contrast-enhanced US for HCC: Finally out from the waiting list?
Authors: Richard G. Barr, Luigi Bolondi
Journal: Hepatology (2023)

1Professor of Radiology, Northeastern Ohio Medical University, Southwoods Imaging, Youngstown, Ohio 44512 2Honorary Professor of the University of Bologna, Italy 3President of the Academy of Sciences of Bologna, Italy, Strada Maggiore 48, Bologna, 4015 Correspondence Honorary Professor of the University of Bologna, Italy, President of the Academy of Sciences of Bologna, Italy, Strada Maggiore 48, Bologna, 4015. Email: [email protected]